Physical Characterization and In Vitro Biological Impact of Highly Aggregated Antibodies Separated into Size-Enriched Populations by Fluorescence-Activated Cell Sorting

被引:52
作者
Telikepalli, Srivalli [1 ]
Shinogle, Heather E. [2 ]
Thapa, Prem S. [2 ]
Kim, Jae Hyun [1 ]
Deshpande, Meghana [3 ]
Jawa, Vibha [3 ]
Middaugh, C. Russell [1 ]
Narhi, Linda O. [4 ]
Joubert, Marisa K. [4 ]
Volkin, David B. [1 ]
机构
[1] Univ Kansas, Macromol & Vaccine Stabilizat Ctr, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[2] Univ Kansas, Microscopy & Analyt Imaging Lab, Lawrence, KS 66045 USA
[3] Amgen Inc, Dept Clin Immunol, Thousand Oaks, CA 91320 USA
[4] Amgen Inc, Dept Proc Dev, Thousand Oaks, CA 91320 USA
关键词
proteins; protein aggregation; particles; monoclonal antibody; IgG; immune response; immunogenicity; PBMC; in vitro; HUMAN GROWTH-HORMONE; HUMAN INTERFERON-BETA; IMMUNE TOLERANT MICE; THERAPEUTIC PROTEINS; STRUCTURAL-CHARACTERIZATION; IMMUNOGENICITY RISK; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; FLOW-CYTOMETRY; WILD-TYPE;
D O I
10.1002/jps.24379
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An IgG2 monoclonal antibody (mAb) solution was subjected to stirring, generating high concentrations of nanometer and subvisible particles, which were then successfully size-enriched into different size bins by low-speed centrifugation or a combination of gravitational sedimentation and fluorescence-activated cell sorting (FACS). The size-fractionated mAb particles were assessed for their ability to elicit the release of cytokines from a population of donor-derived human peripheral blood mononuclear cells (PBMC) at two phases of the immune response. Fractions enriched in nanometer-sized particles showed a lower response than those enriched in micron-sized particles in this assay. Particles of 5-10 m in size displayed elevated cytokine release profiles compared with other size ranges. Stir-stressed mAb particles had amorphous morphology, contained protein with partially altered secondary structure, elevated surface hydrophobicity (compared with controls), and trace levels of elemental fluorine. FACS size-enriched the mAb particle samples, yet did not notably alter the overall morphology or composition of particles as measured by microflow imaging, transmission electron microscopy, and scanning electron microscopy-energy dispersive X-ray spectroscopy. The utility and limitations of FACS for size separation of mAb particles and potential of in vitroPBMC studies to rank-order the immunogenic potential of various types of mAb particles are discussed. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:1575-1591, 2015
引用
收藏
页码:1575 / 1591
页数:17
相关论文
共 64 条
[1]  
Baker Matthew P, 2010, Self Nonself, V1, P314, DOI 10.4161/self.1.4.13904
[2]   Development of a Human Antibody Tolerant Mouse Model to Assess the Immunogenicity Risk Due to Aggregated Biotherapeutics [J].
Bi, Vivian ;
Jawa, Vibha ;
Joubert, Marisa K. ;
Kaliyaperumal, Arunan ;
Eakin, Catherine ;
Richmond, Karen ;
Pan, Oscar ;
Sun, Jilin ;
Hokom, Martha ;
Goletz, Theresa J. ;
Wypych, Jette ;
Zhou, Lei ;
Kerwin, Bruce A. ;
Narhi, Linda O. ;
Arora, Taruna .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (10) :3545-3555
[3]   Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery [J].
Boven, K ;
Knight, J ;
Bader, F ;
Rossert, K ;
Eckardt, KU ;
Casadevall, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 :III33-III40
[4]   Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice [J].
Braun, A ;
Kwee, L ;
Labow, MA ;
Alsenz, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1472-1478
[5]   Immunogenicity of Therapeutic Proteins: The Use of Animal Models [J].
Brinks, Vera ;
Jiskoot, Wim ;
Schellekens, Huub .
PHARMACEUTICAL RESEARCH, 2011, 28 (10) :2379-2385
[6]   What is antibody-mediated pure red cell aplasia (PRCA)? [J].
Casadevall, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 :3-8
[7]   Minimizing the immunogenicity of protein therapeutics [J].
Chirino, AJ ;
Ary, ML ;
Marshall, SA .
DRUG DISCOVERY TODAY, 2004, 9 (02) :82-90
[8]  
CLAMAN HN, 1963, J IMMUNOL, V91, P833
[9]   Protein aggregation and bioprocessing [J].
Cromwell, Mary E. M. ;
Hilario, Eric ;
Jacobson, Fred .
AAPS JOURNAL, 2006, 8 (03) :E572-E579
[10]   Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation [J].
Espargaro, Alba ;
Sabate, Raimon ;
Ventura, Salvador .
MOLECULAR BIOSYSTEMS, 2012, 8 (11) :2839-2844